Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S.

DEERFIELD, Ill., OCT. 7, 2024 — Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company’s commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company’s core assets, and enhancing partnerships with payers, health system providers and life sciences companies.

Jason Stenta, SVP & Chief Commercial Officer

“Jason is a strategic, relationship-driven healthcare leader, and I’m proud to welcome him to the team,” said Mary Langowski, EVP and president, U.S. Healthcare, at Walgreens Boots Alliance. “His experience with complex healthcare organizations, along with his strong understanding of market dynamics, regulatory requirements, and customer needs, will be invaluable as we strengthen our relationships and solutions in healthcare.”

Stenta brings nearly 20 years of healthcare experience, successfully leading large organizations and cross-functional teams through growth and change. Most recently, he was at Optum, a UnitedHealth Group company, where he served as SVP, payer sales. Prior to Optum, he held leadership roles at CVS Health for 10 years.

“This is an exciting time at Walgreens, and I’m thrilled to have this unique opportunity to contribute,” said Stenta. “As we look to expand services, and provide partners with healthcare solutions they really need, I believe Walgreens core strengths and services in retail pharmacy will be key in how we’re able to do this.”

Walgreens also appointed Ramita Tandon as Chief Biopharma Services Officer to lead the company’s unified solutions and offerings to life science and biopharma partners, including clinical trials, commercial patient support and healthcare data and analytics. While Walgreens has a longstanding history and results-driven framework when working with life science and biopharma partners, this new structure will further strengthen Walgreens position as a full-service provider to support product pipelines.

About Walgreens

Walgreens (www.walgreens.com) is included in the U.S. Retail Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. True to its purpose of “more joyful lives through better health,” Walgreens has a more than 120-year heritage of caring for communities and providing trusted pharmacy services, and today is playing a greater role as an independent partner of choice offering healthcare services that improve care, lower costs, and help patients. Operating nearly 9,000 retail locations across the U.S. and Puerto Rico, Walgreens is proud to serve nearly 9 million customers and patients daily. The company’s pharmacists are playing a more critical role in healthcare than ever before, providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for some of the nation’s most underserved populations. Walgreens offers customers and patients a true omnichannel experience, with fully integrated physical and digital platforms designed to deliver high-quality products and healthcare services. Within the U.S. Healthcare segment, Walgreens portfolio also includes businesses in primary care, multi-specialty, post-acute care, urgent care, specialty pharmacy services, population health and provider enablement.